document

PEOPLE

http://biotech.nature.com • OCTOBER 2001 • VOLUME 19 • nature biotechnology

Serge Braun has been named to the positionof vice president, research at Transgene(Strasbourg, France). Dr. Braun joinedTransgene in 1995 as a scientist in the molec-ular and cellular biology department, andserved most recently as deputy vice presi-dent, research.

MDS Pharma Services (Montreal, PQ,Canada) has announced the appointment ofPeter Chiu as pharmacology director andassociate research fellow. Dr. Chiu will alsoassume scientific oversight of the company’sfacility in Taipei, Taiwan, as acting chief sci-entific officer.

Applied Molecular Evolution (San Diego,CA) has announced the appointment ofStanley T. Crooke to its board of directors.Dr. Crooke was formerly president of R&Dfor SmithKline Beecham, and is the founder,chairman, and CEO of Isis Pharmaceuticals.

Patrik Dahlén has been appointed chief exec-utive of BioImage A/S (Copenhagen,Denmark). Dr. Dahlén was formerly presi-dent of the life sciences division ofPerkinElmer.

Patricia Fukami has been appointed vicepresident of finance at diaDexus (SantaClara, CA). She joins diaDexus fromHealthcentral.com, where she served as vicepresident of finance and administration andassisted in the company’s initial public offer-ing in December 1999.

Renovis has announced the appointment ofCorey Goodman as president, chief executiveofficer, and director. Dr. Goodman, the EvanRauch Professor of Neuroscience and direc-tor of the Willis Neuroscience Institute at theUniversity of California, Berkeley, co-found-ed the company in February 2000.

Esperion Therapeutics (Ann Arbor, MI) haselected Antonio M. Gotto Jr. to its board ofdirectors. Dr. Gotto is a professor of medicineas well as the Stephen and Suzanne WeissDean of the Joan and Sanford I. WeillMedical College of Cornell University.

Abgenix (Fremont, CA) has appointed BruceA. Keyt to the position of vice president, pre-clinical development. Dr. Keyt was mostrecently director of biotherapeutic oncologyat Millennium Pharmaceuticals.

Richard Klausner has stepped down as direc-tor of the National Cancer Institute, a posi-tion he has held since 1995. He will becomepresident of the Case Institute of Health,Science and Technology, a new philanthropicenterprise created by the Case Foundation,

the family foundation of AOL Time Warnerchairman Steve Case and his wife Jean.

GPC Biotech AG (Martinsried, Germany andWaltham, MA) has announced the appoint-ment of Steven R. Lazar as vice president,worldwide head of intellectual property. Mr.Lazar was previously managing intellectualproperty counsel at Genzyme.

Henri Lipmanowicz has been named to theboard of directors of Immuno-DesignedMolecules (Paris). Mr. Lipmanowicz recentlyretired after a 30-year career at Merck & Co.,where he was a member of the managementcommittee and president of the MerckIntercontinental Region and Japan. He is cur-rently chairman of the board of trustees ofthe Plexus Institute.

Sangamo BioSciences (Point Richmond,CA) has announced the appointment ofCarl O. Pabo as senior vice president andchief scientific officer. Dr. Pabo comes toSangamo after 10 years as professor of bio-physics and structural biology at theMassachusetts Institute of Technology andinvestigator in the Howard Hughes MedicalInstitute.

Tony Scullion, formerlyvice president and head ofglobal business develop-ment at Glaxo Wellcomeplc, has been named CEOof Memory Pharma- ceuticals (Montvale, NJ).

Genome Therapeutics (Waltham, MA) hasappointed David K. Stone to its board ofdirectors. Mr. Stone is a founding partner ofthe venture capital group AGTC Funds, andwas previously managing director at Cowen& Company (now SG Cowen).

Genencor International (Palo Alto, CA) hasnamed David Thomassen vice president,business development of health care. Dr.Thomassen joins Genencor after serving asdirector of business development atChiron.

Roman Urfer has been appointed vice presi-dent of drug discovery and development atAGY Therapeutics (South San Francisco,CA). Previously, Dr. Urfer served as head ofthe mature drug discovery program in thedepartment of arthritis biology at NovartisPharma AG.

CeNeS Pharmaceuticals (Cambridge, UK)has named Dan Welch to its board as a non-executive director. He is currently presidentof Elan Pharmaceuticals.

987

©20

01 N

atu

re P

ub

lish

ing

Gro

up

h

ttp

://b

iote

ch.n

atu

re.c

om

© 2001 Nature Publishing Group http://biotech.nature.com